200 related articles for article (PubMed ID: 36728908)
1. Acquired EML4-ALK fusion and EGFR C797S in cis mutation as resistance mechanisms to osimertinib in a non-small cell lung cancer patient with EGFR L858R/T790M.
Wang LS; Chen SQ; Zhong X; Jiao XD; Liu K; Qin BD; Wu Y; Ling Y; Duan XP; Zang YS
Anticancer Drugs; 2023 Nov; 34(10):1146-1150. PubMed ID: 36728908
[TBL] [Abstract][Full Text] [Related]
2. BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant EGFR Mutations in Non-Small Cell Lung Cancer.
Lim SM; Fujino T; Kim C; Lee G; Lee YH; Kim DW; Ahn JS; Mitsudomi T; Jin T; Lee SY
Clin Cancer Res; 2023 Aug; 29(16):3004-3016. PubMed ID: 37249619
[TBL] [Abstract][Full Text] [Related]
3. A Phase II Study to Assess the Efficacy of Osimertinib in Patients With EGFR Mutation-positive NSCLC Who Developed Isolated CNS Progression (T790M-negative or Unknown) During First- or Second-generation EGFR-TKI or Systemic Disease Progression (T790M-negative) After Treatment With First- or Second-generation EGFR-TKI and Platinum-based Chemotherapy (WJOG12819L).
Takeda M; Shimokawa M; Nakamura A; Nosaki K; Watanabe Y; Kato T; Hayakawa D; Tanaka H; Takahashi T; Kogure Y; Tachihara M; Fujimoto D; Yamaguchi K; Hamaguchi N; Okamoto I; Azuma K; Hasegawa K; Yamamoto N; Nakagawa K
Clin Lung Cancer; 2021 Jul; 22(4):376-380. PubMed ID: 33612406
[TBL] [Abstract][Full Text] [Related]
4. Uncommon de novo EGFR
Pang LL; Zhuang WT; Huang YH; Liao J; Li MZ; Lv Y; Zhang L; Fang WF
Lung Cancer; 2024 Apr; 190():107528. PubMed ID: 38461768
[TBL] [Abstract][Full Text] [Related]
5. A Phase II Study of Osimertinib Combined With Platinum Plus Pemetrexed in Patients With EGFR-Mutated Advanced Non-Small-cell Lung Cancer: The OPAL Study (NEJ032C/LOGIK1801).
Asahina H; Tanaka K; Morita S; Maemondo M; Seike M; Okamoto I; Oizumi S; Kagamu H; Takahashi K; Kikuchi T; Isobe T; Sugio K; Kobayashi K
Clin Lung Cancer; 2021 Mar; 22(2):147-151. PubMed ID: 33199228
[TBL] [Abstract][Full Text] [Related]
6. MUC1-C Is a Common Driver of Acquired Osimertinib Resistance in NSCLC.
Haratake N; Ozawa H; Morimoto Y; Yamashita N; Daimon T; Bhattacharya A; Wang K; Nakashoji A; Isozaki H; Shimokawa M; Kikutake C; Suyama M; Hashinokuchi A; Takada K; Takenaka T; Yoshizumi T; Mitsudomi T; Hata AN; Kufe D
J Thorac Oncol; 2024 Mar; 19(3):434-450. PubMed ID: 37924972
[TBL] [Abstract][Full Text] [Related]
7. Discovery of a Novel Potent EGFR Inhibitor Against EGFR Activating Mutations and On-Target Resistance in NSCLC.
Lee EJ; Oh SY; Lee YW; Kim JY; Kim MJ; Kim TH; Lee JB; Hong MH; Lim SM; Baum A; Woelflingseder L; Engelhardt H; Petronczki M; Solca F; Yun MR; Cho BC
Clin Cancer Res; 2024 Apr; 30(8):1582-1594. PubMed ID: 38330145
[TBL] [Abstract][Full Text] [Related]
8. Furmonertinib and intrathecal pemetrexed chemotherapy rechallenges osimertinib-refractory leptomeningeal metastasis in a non-small cell lung cancer patient harboring EGFR20 R776S, C797S, and EGFR21 L858R compound EGFR mutations: a case report.
Jia G; Bashir S; Ye M; Li Y; Lai M; Cai L; Xu M
Anticancer Drugs; 2024 Jul; 35(6):542-547. PubMed ID: 38513197
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, and antitumor activity evaluation of potent fourth-generation EGFR inhibitors for treatment of Osimertinib resistant non-small cell lung cancer (NSCLC).
Zhang Y; Tong L; Yan F; Huang P; Zhu CL; Pan C
Bioorg Chem; 2024 Jun; 147():107394. PubMed ID: 38691906
[TBL] [Abstract][Full Text] [Related]
10. Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer.
Uchibori K; Inase N; Araki M; Kamada M; Sato S; Okuno Y; Fujita N; Katayama R
Nat Commun; 2017 Mar; 8():14768. PubMed ID: 28287083
[TBL] [Abstract][Full Text] [Related]
11. EML4-ALK Variant 3a/b as a mechanism of osimertinib resistance in a patient with EGFR L858R positive NSCLC.
Yamaguchi T; Masago K; Sasaki E; Kuroda H; Matsushita H; Horio Y
Cancer Genet; 2024 Jan; 280-281():13-16. PubMed ID: 38128381
[No Abstract] [Full Text] [Related]
12. Brigatinib combined with cetuximab in the fifth-line treatment of non-small cell lung cancer with EGFR p.C797S mutation in critically ill patients: a report of two cases and literature review.
Liu J; Lei H; Zhang D; Zhang N
Anticancer Drugs; 2024 Jul; 35(6):569-575. PubMed ID: 38527281
[TBL] [Abstract][Full Text] [Related]
13. Allelic Context of EGFR C797X-Mutant Lung Cancer Defines Four Subtypes With Heterogeneous Genomic Landscape and Distinct Clinical Outcomes.
Lu C; Wei XW; Wang Z; Zhou Z; Liu YT; Zheng D; He Y; Xie ZH; Li Y; Zhang Y; Zhang YC; Huang ZJ; Mei SQ; Liu JQ; Guan XH; Deng Y; Chen ZH; Tu HY; Xu CR; Chen HJ; Zhong WZ; Yang JJ; Zhang XC; Mok TSK; Wu YL; Zhou Q
J Thorac Oncol; 2024 Apr; 19(4):601-612. PubMed ID: 37981218
[TBL] [Abstract][Full Text] [Related]
14. Patterns of progression on first line osimertinib in patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): A Swiss cohort study.
Schuler A; Huser J; Schmid S; Schär S; Scherz A; Gautschi O; Mauti L; von Briel T; Waibel C; Wannesson L; Pankovics J; Mark MT; Rothschild SI; Addeo A; Janthur WD; Siano M; Boos L; Britschgi C; Früh M
Lung Cancer; 2024 Jan; 187():107427. PubMed ID: 38043395
[TBL] [Abstract][Full Text] [Related]
15. AXIN1/MYC Axis Mediated the Osimertinib Resistance in EGFR Mutant Non-Small Cell Lung Cancer Cells.
Yu H; Wang Z; Dong Y; Li L; Fan X; Zheng N; Jiang J; Lin C; Lu C; Li K; Feng M
Tohoku J Exp Med; 2024 May; 262(4):269-276. PubMed ID: 38233113
[TBL] [Abstract][Full Text] [Related]
16. DNA topoisomerase II inhibition potentiates osimertinib's therapeutic efficacy in EGFR-mutant non-small cell lung cancer models.
Chen Z; Vallega KA; Wang D; Quan Z; Fan S; Wang Q; Leal T; Ramalingam SS; Sun SY
J Clin Invest; 2024 Mar; 134(10):. PubMed ID: 38451729
[TBL] [Abstract][Full Text] [Related]
17. Case report: Clinical complete response in advanced ALK-positive lung squamous cell carcinoma: a case study of successful anti-PD-1 immunotherapy post ALK-TKIs failure.
Yang C; Zeng R; Zha Y; Li Y; Wang T; Zhao R; Li M; Zhang J
Front Immunol; 2024; 15():1360671. PubMed ID: 38380327
[TBL] [Abstract][Full Text] [Related]
18. Primary versus acquired epidermal growth factor receptor Thr790Met mutant non-small cell lung cancer: clinical features and prognoses.
Zhou S; Cai G; Meng X; Li M; Fu Y; Wang X; Wang K; Han X
Clin Transl Oncol; 2024 Jun; 26(6):1395-1406. PubMed ID: 38190033
[TBL] [Abstract][Full Text] [Related]
19. Continuation of osimertinib in EGFR-mutant non-small-cell lung cancer patients bearing CNS metastasis (EPONA study).
Okuma Y; Nomura S; Ninomiya K; Gyotoku H; Murakami S; Kogure Y; Harada D; Okishio K; Okamoto H; Goto Y
Future Oncol; 2023 Jul; 19(22):1515-1521. PubMed ID: 37577772
[TBL] [Abstract][Full Text] [Related]
20. A Novel
Sun Y; Pei L; Luo N; Chen D; Meng L
Onco Targets Ther; 2020; 13():11177-11181. PubMed ID: 33173309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
